Clinical Trial Search

Primary: Number of Participants Experiencing a Flare During Treatment Period 2 — 10; 21 Participants — p=<0.001

Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml

Primary: Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response — 100; 100; 100; 100 Percentage of Participants

Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study — 1 Participants

Primary: Number of Participants With Serious Infections, Opportunistic Infections of Interest and Malignancies: Prospective Participants — 0; 0; 0 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 29; 5 participants

Primary: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase — 13; 20 Participants — p=0.031

Primary: Patient Function Response to Biologic Therapy as Measured by RAPID3 — -1.11 change in score

Primary: Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12 — 11.0; 57.0 percentage of participants…

Primary: Proportion of Participants Who Attain Inactive Disease by 6 Months — 10; 17 participants

Primary: Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12 — 32; 31; 6; 26 Participants — p=<.0001

Primary: Percentage of Participants Who Developed Psoriatic Arthritis (PsA) — 47.4; 35.7; 17.3; 10.3 Percentage of participants

Primary: Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40) — 48.1; 25.6…

Primary: Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16 — 16.0; 33.9 percentage of participants — p=0.0008

Primary: Number and Percentage of Participants With PASI 75 Response — 39; 39 Participants

Primary: Percentage of Participants With Disease Flare in Part 2 — 81; 28 percentage of participants — p=0.0030

Primary: Number of Patients Meeting the Definition of Improvement (DOI) at Week 24: at Least 3 of 6 Core Set Measures (CSM) Improved by ≥ 20% With no More Than 2 CSM Worsening by…

Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants

Primary: Serum Trough Concentration (C-trough) of Golimumab — 0.50 micrograms per milliliter (mcg/mL)

Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…

Primary: Apparent Oral Clearance (CL/F) — 28.09; 25.48; 20.53 liter per hour

Primary: Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B) — NA; 6 months — p=0.0002

Primary: Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16 — 23 Participants

Primary: Composite of All Primary Endpoints — 13; 14; 41; 245 Participants — p=0.7357

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 13; 7; 20; 11 Participants

Primary: Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International…

Primary: Maximum Serum Concentration (Cmax) of Sarilumab at Week 12 — 7.57; 13.7; 22.0; 33.6 milligram per liter (mg/L)

Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 — 11.5; 33.1 percentage of participants — p=<0.0001

Primary: Proportion of ACR 20 Responders at Day 169 — 39.4; 22.3 Percentage of participants — p=<0.001

Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI) — 83.3; 85.7; 85.2; 92.3 percentage of…